The beneficial use of ultramicronized palmitoylethanolamide as add-on therapy to Tapentadol in the treatment of low back pain: a pilot study comparing prospective and retrospective observational arms
Observational studyHumans
- Design
- Observational study
- Subjects
- 55 patients with chronic low back pain: 30 prospective (tapentadol plus PEA) and 25 retrospective (tapentadol alone)
- Dose used in the study
- Ultramicronised PEA added to tapentadol; PEA dose not in the abstract
- Duration
- 6 months
- What was measured
- Pain intensity, neuropathic component, disability and tapentadol dose at baseline and 6 months
What the authors reported
The add-on group had larger reductions in pain, neuropathic component, disability and tapentadol dose than the tapentadol-only group, with no serious side effects.
Limits of this study
Comparison is between a prospective arm and a historical retrospective arm, not a randomised one. Small groups. Open label. PEA dose not in the abstract.
Source
PubMed 29258432 · doi:10.1186/s12871-017-0461-9
Entry checked against the abstract, supplied by Devlin on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.